Study of iloperidone for Schizophrenia Symptoms
This study is looking at how well iloperidone long-acting injection (LAI) works to prevent symptoms from getting worse in people with schizophrenia. Researchers want to see if iloperidone LAI is better than a placebo (an inactive substance designed to look like the study drug) at keeping symptoms stable. You may be able to join if you are 18 to 65 years old, have a diagnosis of schizophrenia, and need ongoing psychiatric treatment. The main goal is to see how long it takes for symptoms to worsen over a period of up to 52 weeks. The current status of this study is unclear, but it plans to enroll about 400 participants.
- Study design
- This is an interventional study comparing iloperidone LAI to a matching placebo. It plans to enroll 400 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 52 weeks after randomization to measure the time to exacerbation of symptoms.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Randomized Withdrawal Study in Patients With Schizophrenia
At a glance
Conditions
Where it's being run
22 sites across 12 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Time to exacerbation of symptomsUp to 52 weeks post-randomization
As measured by the time to first exacerbation of psychiatric symptoms